Log inSign up
Reading a stock page
  • The tabs show the price chart, results, shareholding, events and news for this one company.
  • The Signal Score sums up trend, momentum and quality from past data. It is a description, not a forecast.
  • Every figure names its source. "Official" means it came from NSE or BSE filings.
  • Use the star to watch the stock, or Add to portfolio to record a trade.

Prices during market hours are delayed by up to 15 minutes. Nothing here is a recommendation to buy or sell.

« Dashboard

INDSWFTLAB ☆ BSE also on NSE

IND-SWIFT LABORATORIES LTD. · code 532305 · INE915B01019 · Pharma & Healthcare · series B · Daily price history

330.20 -5.70 (-1.70%) close on 19 Nov 2026
Official NSE & BSE Auto-Sync: Checking Overview, Financials, Technicals, Shareholding & Events in the background...
52

ISA Signal Score: Neutral

Hold or watch: no clear edge. Based on prices to 2026-11-19. Confidence 100%.

Trend60
Momentum25
52-week range74
Volume38
Risk43
Fundamentals72

Working for it

  • Price is above its 200-day average (long-term uptrend)
  • 50-day average is above the 200-day average
  • 50-day average is rising
  • Low debt

Working against it

  • Price is below its 20-day average
  • Price is below its 50-day average
  • MACD is negative and weakening

Red flags

  • Very volatile: it moves about 7.2% on a typical day

Measured reference levels (not forecasts): 20-day low 327.80, 52-week high 413.65, typical daily move 23.88, two typical moves below price 282.44.

A rule-based reading of price, volume and filed numbers. It is information, not investment advice, and it can be wrong. Do your own research.

At a glance

Five quick readings from results and prices. A starting point for your own research, not advice.
QualityWeakROE 0.0%, ROCE 52.8%, almost no debt
GrowthNot knownNeeds at least 3 years of results. More years load on later visits.
ValuationNo earningsP/E cannot be worked out while the company makes a loss.
MomentumStrongAbove its 200-day average, beat NIFTY 50 by 247.5 points
RiskHighSwings 62% a year, fell up to 21% from a peak, beta 0.59

Smart Investor Tips: INDSWFTLAB

Caution Warranted (Trend or Balance-Sheet Headwinds)

Actionable Insights & Positives

  • Pullback within a long-term uptrend: holding above the 200-day average (Rs 231.08) while digesting gains below the 50-day average (Rs 369.97).
  • Tip: Click the star button above to add this stock to your Watchlist and set a target "Buy below" alert price.

Risk Checks & Things to Verify

  • Reported a net loss in FY24. Turnaround stories carry higher execution risk.
  • High 30-day annualized volatility (68%). Keep initial position sizes smaller and use wider stop-review levels.

BSE Authentic Bhavcopy & Cross-Exchange Check No API Key

Runs authentic BSE price & volume verification (latest BSE Bhavcopy snapshot, split-adjusted 52W High/Low, 20/50/200 DMA alignment, and 20-day volume trend, plus cross-listed NSE MCP check when shared by ISIN).

Algorithmic Momentum Prediction & Optimal Entry PriceWEAK / REDUCE ON BOUNCES (Score 31/100)

Weak trend, debt overhang, or distribution. Avoid fresh buying until price reclaims 50-DMA (Rs 369.97). If already held, protect capital if it breaks below Rs 205.04 or trim near resistance Rs 426.00.

Optimal Support areaTranche 1 (50%)Tranche 2 (50%)Risk level / ReviewLevel 1 (Swing)Level 2 (Breakout)Risk : Reward
Rs 317.30 – Rs 330.20
Ideal ~Rs 323.75
Rs 330.20 Rs 317.30 Rs 205.04
ATR 7.2%
Rs 537.43 Rs 679.88 1 : 1.8
RSI 28 · Vol 0.79x
1M 3M 6M 1Y 3Y ALL Investment checklist Download CSV 1M change -6.3% · high 426.00 · low 321.20 · max drawdown -19.2%

Live Candlestick & TradingView Chart (INDSWFTLAB)

MARKET CLOSED - EOD SNAPSHOT
Style:  Timeframe:  Overlays:

Key figures results FY24, price 19 Nov

P/E4.6sector median 44.6
P/B2.09xprice / book value
EPSRs 71.24grew 783.9% a year
Dividend yield-from saved dividend events
Debt to equity0.02xmore cash than debt
Sales growth6.1%a year over 1 years
Profit growth-yearly, needs 2+ years
Operating margin50.0%net margin 0.0%

From the official NSE results filings, consolidated. P/E uses the last full year's EPS, EV/EBITDA 2.4. See all years.

Company Debt, Borrowings & Cash Flow Health (Official FY24 Consolidated Filing)

Auto-extracted from official NSE/BSE XBRL Balance Sheet & Cash Flow statements (Rs Crore).

Strong Balance Sheet & Cash Flow · Score 75/100
Total Debt / Loans Rs 16.6 Cr Reduced Rs 845 Cr YoY
Cash & Bank Balances Rs 432 Cr Liquid cash & equivalents
Net Debt (Loans − Cash) Net Cash Rs 415 Cr Debt-free on net basis
Debt to Equity & Interest Cover 0.02x D/E Interest cover: 12.4x EBIT
Operating Cash Flow (OCF) Rs -181 Cr Cash generated from operations
Free Cash Flow (FCF) Rs -225 Cr After Capex of Rs 44.5 Cr
  • Net Cash / Debt-Free balance sheet (Cash Rs 432 Cr exceeds Total Loans Rs 16.6 Cr).
  • De-leveraging: reduced total debt by Rs 845 Cr YoY.
  • Strong loan interest coverage (12.4x EBIT/Interest).
  • Negative Operating Cash Flow (Rs -181 Cr) in latest filing.
  • Free Cash Flow is Rs -225 Cr due to Capex investment of Rs 44.5 Cr.

About IND-SWIFT LABORATORIES

Healthcare

No company description saved yet. Use Profile below to read about this company.

Listed on BSE NSE

Market capRs 1,951 CrSmall cap · 5.91 Cr shares
First listed02 Jul 1997BSE not available · NSE 02 Jul 1997
Face valueRs 10
Book valueRs 157.64Price is 2.1x book value
ROE0.0%weak, below 8%
ROCE67.1%good, above 15%

NSE results filing: shares, book value, ROE, ROCE · NSE: listing date, face value · ratios as of FY2024

Profile completeness7 of 8Missing: description · ratios as of FY2024

Checked: BSE 20 Nov 2026. Yahoo Finance did not answer (HTTP 0).

Profile, History and Financial records open a web search for this company in a new tab.

Shareholding

Promoters and group 42.93%, public 57.07%, as on 30 Sep 2026. Holder names and history

Day range327.00 to 336.75Open 335.95
52-week high426.00 -22.5% from high (30 Oct 2026)
52-week low87.00 +279.5% from low (09 Dec 2025)
Volume19,105 0.3x the 20-day average
RSI (14)41 neutral
Volatility (30d)68.4%annualised
87.00
426.00

Returns

1W-8.2%
1M-6.3%
3M-0.9%
6M+143.2%
1Y+245.4%
YTD+274.4%
3Y a year+51.7%
5Y a year+35.0%

Against the NIFTY 50

PeriodINDSWFTLABNIFTY 50Difference
1M-6.3%+11.5% -17.8 pts
3M-0.9%+5.3% -6.2 pts
6M+143.2%+7.9% +135.3 pts
1Y+245.4%-2.1% +247.5 pts

Risk over the past year

Volatility62%high
Deepest fall-20.8%from a peak
Beta0.59moves less than the index
Best day+20.0%11 Aug 2026
Worst day-10.1%30 Oct 2026
Up days51%of sessions

Returns use closing prices. Bonus issues and splits are adjusted automatically when detected. Beta compares daily moves with the NIFTY 50 over 246 shared sessions.

AI analysis

Company turnover, products, risks and entry ideas, written by the AI provider you set up in Settings.

Open AI analysis

🛡 Forensic Financial Health: Piotroski F-Score & 3-Step DuPont ROE Decomposition

Institutional balance-sheet quality, earnings-to-cash conversion, and ROE driver breakdown from official XBRL filings.

Piotroski F-Score: 5 / 9 · Solid Financial Health
3-Step DuPont ROE Identity: Balanced Profitability & Efficiency
Net Margin: 0.0% × Asset Turnover: 1.10x × Equity Multiplier: 1.25x = ROE 0.0%
⚠ Positive Net Profit (PAT > 0) Rs 0 Cr
⚠ Positive Operating Cash Flow (OCF > 0) Rs -181 Cr
⚠ High Cash Conversion (OCF >= 85% of PAT) N/A
✓ Improving Return on Assets (ROA YoY) 0.0% vs 0.0%
✓ Conservative / Decreasing Debt-to-Equity 0.02x (prev 1.26x)
✓ Healthy Balance Sheet Asset Coverage 5.27x
⚠ Institutional Return on Equity (ROE >= 14%) 0.0%
✓ Stable / Expanding Profit Margin YoY 0.0% vs 0.0%
✓ Asset Turnover Efficiency (Sales / Assets) 1.10x

Quarterly Results (Last 8 Quarters — QoQ & YoY Acceleration) Rs crore

Rs crore Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales / Revenue 1.41138153159151170191240
Sales QoQ % -48.0%+9687.2%+10.9%+3.9%-5.0%+12.6%+12.4%+25.7%
Operating Profit -8.81-10.03.007.004.0021.035.045.0
Operating Margin (OPM %) -624.8%-7.2%2.0%4.4%2.6%12.4%18.3%18.8%
Net Profit (PAT) 4.642229.008.0010.015.025.034.0
Profit QoQ % +1350.0%+4684.5%-95.9%-11.1%+25.0%+50.0%+66.7%+36.0%
Profit YoY % -78.6%-36.5%+45.4%+2400.0%+115.5%-93.2%+177.8%+325.0%
Net Margin % 329.1%160.9%5.9%5.0%6.6%8.8%13.1%14.2%

Sales and profit Rs crore, consolidated

Sales growth+6.1%a year, 1Y
Profit growth-a year, 1Y
EPS growth+783.9%a year, 1Y
Avg ROE0.0%2 years

Profit and loss

Rs croreFY23FY24
Sales1,2071,281
Sales growth-+6.1%
Operating profit203641
Operating margin16.8%50.0%
Other income33.545.4
Interest92.251.1
Depreciation57.453.3
Profit before tax86.5582
Tax rate44.7%26.0%
Net profit00
Profit growth--
Net margin0.0%0.0%
EPS (Rs)8.0671.24

Balance sheet

Rs croreFY23FY24
Equity (net worth)682931
Borrowings86216.6
Cash18.2432
Total assets1,8241,165
Debt to equity1.26x0.02x

Debt, Loans, Cash Flow & Working Capital

Rs croreFY23FY24
Operating Cash Flow (OCF)195-181
Capital Expenditure (Capex)12.844.5
Free Cash Flow (FCF = OCF - Capex)182-225
OCF / Net Profit Conversion--
Total Borrowings / Loans86216.6
Cash & Bank Balances18.2432
Trade Receivables (Cr)505169
Receivable Days152.77x48.19x
Inventories (Cr)43910.5
Inventory Days132.60x2.98x

Returns on capital

Rs croreFY23FY24
ROE0.0%0.0%
ROCE12.3%52.8%
Interest cover1.94x12.38x

Read from the official annual results filed with NSE (XBRL), consolidated figures. ROE uses average equity of the year and the year before when both are saved, ROCE uses profit before interest and tax over total assets less current liabilities. EPS is per today's share. More years are loading and will appear on a later visit. Check the annual report before investing.

Compared with its sector Pharma & Healthcare

StockPriceDay1 yearMkt cap (Cr)P/EP/BROENet margin
ALIVUSALIVUS LIFE SCIENCES LIMITED 1,449.85 +0.3% - 17,768 37.7 7.6 20.2% 20.6%
CAPLIPOINTCAPLIN POINT LABORATORIES LTD. 2,085.40 -0.0% - 15,839 34.6 6.8 19.7% 27.0%
ASTRAZENASTRAZENECA PHARMA INDIA LTD. 6,120.45 +1.9% - 15,301 94.7 21.5 22.7% 12.5%
AARTIPHARMAarti Pharmalabs Limited 1,024.80 +1.3% - 9,287 42.8 5.3 12.3% 11.7%
BLUEJETBlue Jet Healthcare Limited 516.80 -0.2% - 8,964 54.7 10.6 19.4% 23.0%
CIPLACIPLA LTD. 1,416.00 -0.3% - - 29.5 - - 13.7%
ALKEMAlkem Laboratories Limited 5,145.00 -1.1% - - 26.7 - 17.0% 16.0%
DIVISLABDIVIS LABORATORIES LTD. 11,178.00 +1.0% - - 115.6 - 15.3% 24.3%
WOCKPHARMAWOCKHARDT LTD. 2,186.60 +7.9% - - - - - -
RUBICONRUBICON RESEARCH LIMITED 1,726.00 +3.9% - - - - - -
APOLLOHOSPAPOLLO HOSPITALS ENTERPRISE LT 8,744.80 -0.8% - - 64.8 - 21.1% 7.9%
RAINBOWRainbow Children's Medicare Li 1,241.45 -1.3% - - - - - -
Sector median- 44.67.617.0%

The 12 largest of 80 stocks in this sector on BSE, by market cap where known and traded value otherwise. Valuation shows for stocks whose results this site has read; it fills in as people open more stock pages. Prices from 19 Nov 2026.

Today: 15 minute chart and signal

Opens when you view this tab.

Analysis and next-session reading

Opens when you view this tab.

Complete analysis report Financials, shareholding, events, risks and a data reliability score.

Signals

Price is below its 50-day average 20-day average is below the 50-day (short-term downtrend) Price is above its 200-day average (long-term uptrend) RSI 41: neutral

Simple rules applied to end-of-day prices. They describe what the chart is doing and are not advice to buy or sell.

When is a good price? from this stock's own price history

The price is in the upper half of its 1-year range and is lower than it was on 23% of days in the past year.

Support (prices below today's)

20-day low321.20-2.7%
60-day low317.30-3.9%
200-day average231.08-30.0%
52-week low87.00-73.7%

Resistance (prices above today's)

50-day average369.97+12.0%
20-day high426.00+29.0%
60-day high426.00+29.0%
52-week high426.00+29.0%

Zones buyers often watch

Lower quarter of the 1-year range 87.00 to 171.75 Historically the cheapest part of the past year.
Pullback of 10% to 20% from the high 340.80 to 383.40 A common area for dips inside an uptrend.
Around the 200-day average 224.15 to 238.02 Long-term trend line, often watched as support.

Deepest fall from a peak in the past year: -20.8%. Currently -20.2% below its latest peak. Levels are from history and do not predict where the price will go.

Moving averages and momentum

IndicatorValueReading
20-day average354.46 Price is 6.8% below
50-day average369.97 Price is 10.8% below
200-day average231.08 Price is 42.9% above
RSI (14)41Neutral
MACD (12, 26, 9)-7.04Below its signal line (momentum fading)
Volatility (30d)68.4%High yearly swings

Support and resistance

R2341.07
R1335.63
Pivot331.32
S1325.88
S2321.57

Classic pivot levels from the latest session's high, low and close. Prices often pause near them, but they are only reference points.

DateOpenHighLow CloseChangeVolume
2026-11-19 335.95 336.75 327.00 330.20 -1.70% 19,105
2026-11-18 335.80 339.00 325.25 335.90 +1.02% 48,171
2026-11-17 339.55 345.40 330.00 332.50 -4.90% 51,479
2026-11-16 371.65 371.65 344.00 349.65 -3.21% 22,772
2026-11-13 362.95 363.00 350.85 361.25 +0.49% 17,778
2026-11-12 363.25 366.75 357.80 359.50 -0.75% 23,682
2026-11-11 352.00 364.90 350.00 362.20 +3.63% 30,812
2026-11-09 335.95 352.75 332.45 349.50 +3.62% 30,347
2026-11-06 358.35 361.60 343.40 347.60 -2.48% 20,758
2026-11-05 382.40 382.40 355.00 356.45 -4.09% 71,060
2026-11-04 347.00 373.60 346.95 371.65 +8.43% 34,438
2026-11-03 356.50 367.85 338.40 342.75 -3.23% 51,733
2026-11-02 372.95 375.70 347.40 354.20 -3.59% 80,313
2026-10-30 417.85 426.00 353.45 367.40 -10.14% 212,154
2026-10-29 380.00 424.15 373.90 408.85 +7.75% 194,553
2026-10-28 378.10 381.55 364.15 379.45 +3.04% 34,045
2026-10-27 332.90 375.00 332.90 368.25 +8.97% 60,848
2026-10-26 321.20 343.75 321.20 337.95 +3.10% 30,124
2026-10-23 347.00 348.45 322.05 327.80 -5.31% 78,442
2026-10-22 336.10 349.65 336.10 346.20 +1.15% 17,523
2026-10-21 352.40 365.00 337.30 342.25 -2.88% 68,508
2026-10-19 359.45 364.15 350.50 352.40 -1.87% 14,605

News from the last 15 days More

Shareholding pattern

Up to dateNSE listingChecks passed

Quarter ended 30 Sep 2026, filed 15 Oct 2026. Latest filing is for the expected quarter (Sep 2026). Company: IND SWIFT LABORATORIES LT, ISIN INE915B01019.

Promoters and group
42.93%
0.00 pp vs Jun 2026
Public (all, Category B)
57.07%
0.00 pp vs Jun 2026

Foreign, domestic institution and mutual fund lines need the filing file for the period. An admin can load them under Admin > Shareholding tracker.

Ownership split

Trend

Latest quarter compared

CategoryPrevious (Jun 26)Latest (Sep 26)Change (pp)Change in sharesYear earlier (pp)What it may mean
Promoters and group42.93%42.93%0.00 pp-+3.43 ppNo material change.
Public (all, Category B)57.07%57.07%0.00 pp--3.43 ppNo material change.

Change is in percentage points (latest percent minus previous percent), not a relative change. Mutual funds and insurers are part of domestic institutions and are never added to it. Only comparable quarters (1 to 6 months apart; about a year for the year-earlier column) are compared.

Insights and risk alerts

No rule was triggered by the data in the database. That is not a clean bill of health: the rules look only at reported holdings.

These alerts describe reported ownership. They are not buy or sell advice. Judge the company with its results, debt, valuation and announcements.

Who holds the shares

The exchange listing has no filing file for this stock, so holder names are not available.

Quarter by quarter

Quarter endedPromotersChangePublicChangeFiledSource
Sep 202642.93%-57.07%-15 Oct 2026NSE
Sep 202642.93%0.00 pp57.07%0.00 pp25 Sep 2026NSE
Jun 202642.93%-0.06 pp57.07%+0.06 pp20 Jul 2026NSE
Mar 202642.99%-0.07 pp57.01%+0.07 pp21 Apr 2026NSE
Feb 202643.06%+3.56 pp56.94%-3.56 pp05 Mar 2026NSE
Dec 202539.50%0.00 pp60.50%0.00 pp21 Jan 2026NSE
Sep 202539.50%0.00 pp60.50%0.00 pp20 Oct 2025NSE
Aug 202539.50%-60.50%-05 Sep 2025NSE
Aug 202537.72%+0.95 pp62.28%-0.95 pp07 Aug 2025NSE
Jul 202536.77%-63.23%-28 Jul 2025NSE
Jul 2025 revised38.57%-2.37 pp61.43%+2.37 pp11 Jul 2025NSE
Jun 202540.94%0.00 pp59.06%0.00 pp11 Jul 2025NSE
Mar 202540.94%-59.06%-19 Apr 2025NSE
Mar 2025 revised40.94%-1.06 pp59.06%+1.06 pp24 Mar 2025NSE
Dec 202442.00%0.00 pp58.00%0.00 pp21 Jan 2025NSE
Sep 2024 revised42.00%0.00 pp58.00%0.00 pp21 Oct 2024NSE
Aug 202442.00%0.00 pp58.00%0.00 pp08 Sep 2024NSE
Jun 2024 revised42.00%0.00 pp58.00%0.00 pp16 Jul 2024NSE
Mar 202442.00%0.00 pp58.00%0.00 pp20 Apr 2024NSE
Dec 202342.00%0.00 pp58.00%0.00 pp18 Jan 2024NSE
Sep 202342.00%0.00 pp58.00%0.00 pp18 Oct 2023NSE
Jun 202342.00%0.00 pp58.00%0.00 pp21 Jul 2023NSE
Mar 202342.00%0.00 pp58.00%0.00 pp17 Apr 2023NSE
Dec 202242.00%0.00 pp58.00%0.00 pp20 Jan 2023NSE
Shareholding details

Loading...

Events

Not checked yet

BSE events come from the BSE corporate actions file, which an admin uploads. There is no automatic BSE fetch. Nothing has been imported for this stock yet.

No events saved for this stock yet.

Fetched from NSE automatically and saved on this site, so past events stay available. Ex date is the first day the stock trades without the benefit; a bonus or split is applied to old prices on its own from that day. Confirm on the exchange website before acting.

ISA shows information and signals worked out from past prices and company filings. They are not recommendations to buy, sell or hold any security, and ISA is not a SEBI-registered investment adviser or research analyst. Prices may be delayed. Check with a registered adviser before you invest.